ASND Ascendis Pharma A/S

252.73USD-1.26%Mkt Cap: 16.58B USDP/E: 17.55

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for …

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap16.58B USD
Enterprise Value16.27B USD
Revenue (TTM)1.32B USD
Gross Profit687.24M USD
Net Income (TTM)-250.65M USD
Revenue/Share20.91 USD
Last Price252.73 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees1.2K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)17.55
P/E (Forward)20.88
PEG—
EV/EBITDA43.09
EV/Revenue12.31
P/S13.78
P/B9.83
EPS (TTM)16.72 USD
EPS (Forward)13.31 USD
52W Range
186.0572% of range278.56
52W High278.56 USD
52W Low186.05 USD
Profitability
Gross Margin86.82%
Oper. Margin30.94%
EBITDA Margin31.39%
Profit Margin-31.67%
ROE140.05%
ROA-17.51%
ROIC-146.65%
ROCE-58.44%
Growth
Revenue Growth73.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF59.24M USD
CapEx (TTM)9.33M USD
FCF Margin11.70%
FCF Yield0.93%
Net Debt-567.80M USD
Net Debt/EBITDA-1.37
Net Debt/FCF-3.67
Balance Sheet
Debt/Equity-5.35
Current Ratio2.89
Quick Ratio2.22
Book Value/Sh28.25 USD
Cash/Share16.16 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)314.90 USD
Upside (mean)+24.6%
Target Range271.92 USD – 353.30 USD
271.92+24.6% to mean353.30
# Analysts21
Ownership
Shares Out.65.60M
Float65.56M
Insiders0.79%
Institutions104.48%
Short Interest
Short Ratio4.2d
Short % Float5.41%
Short % Out.4.57%
Shares Short3.00M
Short (prev mo.)3.48M
Technical
SMA 50242.90 (+4.0%)
SMA 200240.54 (+5.1%)
Beta—
S&P 52W Chg12.00%
Avg Vol (30d)686.77K
Avg Vol (10d)818.20K
Technical Indicators
RSI (14)48.6
MACD6.0811
MACD Signal6.8834
MACD Hist.-0.8023
BB Upper275.70 USD
BB Middle257.61 USD
BB Lower239.52 USD
BB Width14.04%
ATR (14)7.765 USD
Vol Ratio (20d)0.74x

About Ascendis Pharma (NASDAQ: ASND)

›

Ascendis Pharma (NASDAQ: ASND) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1,189 employees.

The shares were at 252.73 USD on 20 November 2026, up 31.9% over 52 weeks. Its 52-week range is 186.05 USD to 278.56 USD: the price is 9.3% below the high and 35.8% above the low.

At a market capitalisation of 16.58B USD, it trades at 17.6 times trailing earnings and 20.9 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 34.3, a discount of 49% for ASND.

Ascendis Pharma reports return on equity of 140.1%, an operating margin of 30.9% and revenue up 73.0% year over year.

It holds more cash than debt, a net cash position of 516.56M EUR. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 21 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 314.90 USD is 24.6% above the current price.